The Myopia Podcast
Introducing "The Myopia Podcast" hosted by David Kading, a leading myopia educator and founder of a renowned myopia clinic in Seattle. This bite-sized podcast is specifically designed to empower and educate eyecare providers in the field of myopia management.
In each episode, David Kading dives into the latest research, innovations, and clinical methods to enhance the effectiveness of managing myopic children. Whether you're an optometrist, ophthalmologist, or a passionate eyecare professional, this podcast provides invaluable insights and practical knowledge to elevate your expertise.
With a perfect blend of education and entertainment, "The Myopia Podcast" keeps you engaged throughout. David's expertise and engaging style make complex concepts accessible and relatable. The episodes are thoughtfully curated to deliver concise and impactful content, ensuring that each episode can be enjoyed within a convenient timeframe of under 30 minutes.
Stay up-to-date with the rapidly evolving field of myopia management as "The Myopia Podcast" unveils expert interviews, case studies, success stories, and evidence-based strategies. Discover new perspectives, learn about emerging technologies, and explore innovative practice management techniques to optimize your approach in managing myopic children.
Join the community of eyecare providers dedicated to providing the best care for their myopic patients. Tune in to "The Myopia Podcast" and unlock a wealth of knowledge that will transform your practice and make a lasting impact on the lives of your young patients.
The Myopia Podcast
#109 The Myopia Podcast: What happened with Sydnexus and the FDA with Patrick Johnson
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Send us Fan Mail
- Petition · Urgent Call for U.S. Children to Have Access to an FDA-Approved Low-Dose Atropine - United States · Change.org
About Patrick Johnson, Ph.D.
Patrick Johnson joined Sydnexis as Chief Business Officer in 2017. He was instrumental in the Series A and B financings at Sydnexis as well as the corporate alliance with Santen Pharmaceuticals that was established in 2021.
Prior to his role at Sydnexis, Patrick was the Vice President of Corporate and Business Development at Allergan, a publicly traded, large-cap pharmaceutical company. At Allergan, Patrick was responsible for establishing dozens of corporate partnerships as well as mergers and acquisitions in eyecare (Allergan’s largest therapeutic area) and drug delivery. Prior to Allergan, Patrick was a co-founder of Chimeros, a biotechnology start-up company founded in Santa Barbara in 2005, where he was Vice President of Business Development in addition to leading scientific teams as Director of Biology. Before co-founding Chimeros, Patrick was an adjunct faculty member at the University of California, Santa Barbara (USCB) where he was simultaneously conducting research in the Center for the Study of Macular Degeneration while teaching classes in Neurobiology, Developmental Biology, Introductory Biology, and Biotechnology and Society.
Patrick holds a B.S. in biopsychology and a Ph.D. in molecular, cellular, and developmental biology, both from USCB. His doctoral research focused on the development of visual pathways in mammals and his post-doctoral research focused on diseases of the eye, spanning both acute injury (retinal detachment) and chronic disease (age-related macular degeneration).